河北中医药学报
河北中醫藥學報
하북중의약학보
JOURNAL OF HEBEI TRADITIONAL CHINESE MEDICINE AND PHARMACOLOGY
2015年
2期
1-3,7
,共4页
张一昕%邓国兴%吴中秋%于文涛%徐晶%韩雪%潘思彤
張一昕%鄧國興%吳中鞦%于文濤%徐晶%韓雪%潘思彤
장일흔%산국흥%오중추%우문도%서정%한설%반사동
消瘀化痰中药%非酒精性脂肪肝%肝X受体%ATP结合盒转运蛋白A1
消瘀化痰中藥%非酒精性脂肪肝%肝X受體%ATP結閤盒轉運蛋白A1
소어화담중약%비주정성지방간%간X수체%ATP결합합전운단백A1
Xiaotan Huayu medicine ( Chinese medicine of dispersing blood stasis and resolving phlegm)%nonacohol fatty liv-er%liver X receptor ( LXR)%ABCA1
目的::观察消痰化瘀中药对非酒精性脂肪肝(NAFLD)大鼠脂质代谢和肝脏LXRα和ABCA1mRNA表达的影响,探讨其作用机理。方法:随机将SD雄性大鼠分正常对照组、模型对照组、东宝肝泰对照组以及消痰化瘀中药高、中、低剂量组,一边造模一边灌胃给予相应药物。用药8周后,检测各组大鼠血清TC、 TG、 HDL、LDL、 FFA和肝组织中TC、 TG的含量改变,并观察肝组织LXRα mRNA和小肠ABCA1表达变化以及肝组织形态学的变化。结果:消瘀化痰中药能降低模型大鼠TC、 TG、 FFA、 ALT、 AST的含量或活性,促使LXRα mRNA和ABCA1的表达上调,改善肝组织的病变程度。结论:调控LXRα/ABCA1通路相关基因,促进肝脏脂质代谢,可能是消痰化瘀中药对NAFLD的治疗作用靶点之一。
目的::觀察消痰化瘀中藥對非酒精性脂肪肝(NAFLD)大鼠脂質代謝和肝髒LXRα和ABCA1mRNA錶達的影響,探討其作用機理。方法:隨機將SD雄性大鼠分正常對照組、模型對照組、東寶肝泰對照組以及消痰化瘀中藥高、中、低劑量組,一邊造模一邊灌胃給予相應藥物。用藥8週後,檢測各組大鼠血清TC、 TG、 HDL、LDL、 FFA和肝組織中TC、 TG的含量改變,併觀察肝組織LXRα mRNA和小腸ABCA1錶達變化以及肝組織形態學的變化。結果:消瘀化痰中藥能降低模型大鼠TC、 TG、 FFA、 ALT、 AST的含量或活性,促使LXRα mRNA和ABCA1的錶達上調,改善肝組織的病變程度。結論:調控LXRα/ABCA1通路相關基因,促進肝髒脂質代謝,可能是消痰化瘀中藥對NAFLD的治療作用靶點之一。
목적::관찰소담화어중약대비주정성지방간(NAFLD)대서지질대사화간장LXRα화ABCA1mRNA표체적영향,탐토기작용궤리。방법:수궤장SD웅성대서분정상대조조、모형대조조、동보간태대조조이급소담화어중약고、중、저제량조,일변조모일변관위급여상응약물。용약8주후,검측각조대서혈청TC、 TG、 HDL、LDL、 FFA화간조직중TC、 TG적함량개변,병관찰간조직LXRα mRNA화소장ABCA1표체변화이급간조직형태학적변화。결과:소어화담중약능강저모형대서TC、 TG、 FFA、 ALT、 AST적함량혹활성,촉사LXRα mRNA화ABCA1적표체상조,개선간조직적병변정도。결론:조공LXRα/ABCA1통로상관기인,촉진간장지질대사,가능시소담화어중약대NAFLD적치료작용파점지일。
Objective:to observe the effect of Chinese Xiaotan Huayu medicine on LXRαmRNA and ABCAI expressions of rats with NAFLD, and to explore its mechanism. Methods: SD rats were randomly divided into control group, model group, Dongbao Gantai group, high-dose, medium-dose and low-dose Chinese medicine groups, administrated with corresponding drugs while models being in-duced. 8 weeks later, detect TC, TG, HDL, LDL, FFA in serum and TC, TG content in hepatic tissue, and observe LXRαmRNA and ABCA1 expressions, and the changes of hepatic histomorphology. Results:Xiaotan Huayu medicine could decrease the content or activity of TC, TG, FFA, ALT and AST, facilitate the LXRαmRNA and ABCA1 expressions increasing, and improve the pathological changes of hepatic tissues. Conclusion:Regulating related gene of LXRα/ABCA1 access and promoting hepatic lipid metabolism may be one of the target points of treating NAFLD with Chinese medicine.